204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study
T.W. Flaig; B.D. Curti; M.S. Gordon; P.J. Van Veldhuizen; W.H. Miller; M.S. Ernstoff; S. Bhatia; N.H. Hunder; N. Royer; J.A. Thompson
- 作者T.W. Flaig; B.D. Curti; M.S. Gordon; P.J. Van Veldhuizen; W.H. Miller; M.S. Ernstoff; S. Bhatia; N.H. Hunder; N. Royer; J.A. Thompson
- 卷第6卷
- 期第12期
- 文件大小76.23KB
- 发表时间2008
- DOI10.1016/s1359-6349(08)72136-0
- 页码64-65